HEX
Potent GH secretagogue in human studies. The GH response fell by about 45% over 16 weeks and recovered after 4 weeks off (Rahim 1998).
Regulatory status (as of Sept 2026)
Not FDA-approved. Not among the peptides named in the 2026 PCAC actions.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote3 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Hexarelin is a compound with only early, small human studies so far. Potent GH secretagogue in human studies.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Phase 1 / early human |
| Dosing | Published research: 1 µg/kg IV bolus in women details1 µg/kg i.v. bolus in women (Popovic 1997). Twice-daily s.c. injections for 16 weeks in healthy elderly adults, n=12 (Rahim & Shalet 1998); the dose is in the full text. i.v. use also in exercise studies (de Vries 2004).Community-reportedCommunity-reported: 100–200 mcg, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It acts like the hunger hormone ghrelin to trigger growth hormone release. Ghrelin-receptor agonist (growth hormone secretagogue). In healthy elderly people given hexarelin twice daily for 16 weeks, the GH response attenuated, but the attenuation was partial and reversible (Rahim 1998).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedCommonly reported doses range from 100 to 200 mcg (subcutaneous injection). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Hexarelin | No published PK data found | Subcutaneous injection | Phase 1 / early human |
| CJC-1295 (no DAC) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| CJC-1295 (with DAC) | 6-8 days | Subcutaneous injection | Phase 1 / early human |
| GHRP-2 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
| GHRP-6 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Growth Hormone category. View All Growth Hormone Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.